ducovest

LIFE-B:CA:TSX-Evolve Global Healthcare Enhanced Yield Fund UnHedged Units (CAD)

ETF | Others |

Last Closing

CAD 25.93

Change

0.00 (0.00)%

Market Cap

N/A

Volume

1.10K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Currency: CAD

Country : Canada

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-22 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XEQT:CA iShares Core Equity Portfolio

N/A

 CAD 6.64B
XEF-U:CA iShares Core MSCI EAFE IMI Ind..

N/A

 CAD 6.19B
CASH:CA GLOBAL X HIGH INTEREST SAVINGS..

N/A

 CAD 5.91B
PHYS-U:CA Sprott Physical Gold Trust

N/A

 CAD 4.76B
XUS-U:CA iShares Core S&P 500 Index ETF

N/A

 CAD 4.54B
HXT-U:CA Global X S&P/TSX 60 Index ETF

N/A

 CAD 3.92B
CEF-U:CA Sprott Physical Gold and Silve..

N/A

 CAD 3.78B
PSLV-U:CA Sprott Physical Silver Trust

N/A

 CAD 3.29B
ZMMK:CA BMO Money Market Fund ETF Seri..

N/A

 CAD 3.24B
NSCB:CA NBI Sustainable Canadian Bond ..

N/A

 CAD 2.78B

ETFs Containing LIFE-B:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.33% 94% A 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.33% 94% A 86% B+
Trailing 12 Months  
Capital Gain 1.37% 18% F 24% F
Dividend Return 6.25% 89% A- 86% B+
Total Return 7.62% 33% F 33% F
Trailing 5 Years  
Capital Gain 11.96% 40% F 47% F
Dividend Return 36.18% 92% A 90% A-
Total Return 48.14% 63% D 58% F
Average Annual (5 Year Horizon)  
Capital Gain 2.30% 44% F 41% F
Dividend Return 3.01% 44% F 35% F
Total Return 0.71% 77% C+ 33% F
Risk Return Profile  
Volatility (Standard Deviation) 5.97% 76% C+ 88% B+
Risk Adjusted Return 50.43% 59% D- 60% D-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.